Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2006

View Archived Issues

Mechanism of cystatin C and E-64 action on osteoclast differentiation elucidated

Phase IIb adrenomyeloneuropathy study of RPI-78M cleared to begin

Agreement for animal study of human fibroblast growth factor-1 in osteoporosis

Alkermes licenses novel opioid receptor compounds discovered at Rensselaer

Gabapentin GR study in diabetic peripheral neuropathy completes enrollment

Influenza protecting virus developed at U. of Warwick

Grant to study two new drug classes in HIV-related nerve damage

Targanta updates preclinical studies of their lead antibiotic candidate oritavancin

Brivaracetam to enter clinical trials as an add-on therapy for Unverricht-Lundborg disease

U.K. approval for phase III cystic fibrosis study of Bronchitol to begin

Genentech files IND for Hedgehog antagonist from Curis collaboration

Novo Nordisk reveals plans for new clinical trials into 2007

SPA completed for Genasense plus chemotherapy in CLL

FX-06 studied in new phase II trial for reperfusion injury

Approvable letter for NRP-104 in ADHD

Myodur IND for Duchenne muscular dystrophy remains on hold

Pharming receives orphan product grant for Rhucin

Symbicort SMART completes European mutual recognition procedure

Ceplene filed for European approval in AML

Recent patents report novel treatment strategies for respiratory disorders

Tykerb filed for European approval in advanced breast cancer

Remicade approved in E.U. for second-line therapy for Crohn's disease

Recent patents report new treatments for depression, psychosis, sleep disorders, etc.

HIV reverse transcriptase inhibitors emerge from Roche R&D

R&D highlights from the UBS Global Life Sciences Conference in New York: Metabolic Pharmaceuticals

Novel antmicrobial biomimetic compounds developed at PolyMedix show efficacy in vivo

Taisho's new ketolide shows promising in vitro and in vivo activity

Paratek and Merck & Co.'s MK-2764 preclinical activity profiled at the ICAAC meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...